Patents Assigned to Cell Therapeutics, Inc.
  • Method of screening compounds that inhibit lysophosphatidic acid acyltransferase
    Publication number: 20040043465
    Abstract: Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
    Type: Application
    Filed: September 23, 2003
    Publication date: March 4, 2004
    Applicant: CELL THERAPEUTICS, INC.
    Inventors: David W. Leung, Daniel Adourel, David Hollenback
  • Hydroxyl-containing compounds
    Patent number: 6693105
    Abstract: Disclosed are therapeutic compounds having the formula: (R)j—(CORE MOIETY), including resolved enantiomers, diastereomers, hydrates, salts, solvates or mixtures thereof where j is an integer from one to three. The core moiety is a bicyclic ring structure having at least one heterocyclic ring that contains five to six ring atoms and up to two nitrogen heteroatoms. R is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C1-6 alkyl or C1-6 alkenyl, and at least one R has the formula I: n is an integer from 1 to 20, at least one of X or Y is —OH. Another of X or Y, which is not —OH, is hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2—or (CH3)2—CH2—, and each W1, W2, and W3 is independently hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2— or (CH3)2—CH2—.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: February 17, 2004
    Assignee: Cell Therapeutics, Inc.
    Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
  • Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
    Publication number: 20040028750
    Abstract: The present invention relates to arsenic sulfide compounds. The present invention also relates to pharmaceutical compositions useful for treating cancer, such as leukemia or lymphoma, which comprises an arsenic sulfide compound. The present invention further relates to methods for treating cancer, such as leukemia or lymphoma, using an arsenic sulfide compound. Finally, the present invention relates to processes for producing arsenic disulfide (As4S4).
    Type: Application
    Filed: August 7, 2003
    Publication date: February 12, 2004
    Applicant: Cell Therapeutics, Inc.
    Inventor: Daopei Lu
  • Phospholipase D inhibitors and uses thereof
    Publication number: 20040002526
    Abstract: The invention is directed to thiazolidinones and the use thereof to inhibit phospholipase D (PLD) activity. The invention further relates to methods of treating cancer and inflammatory diseases using thiazolidinones.
    Type: Application
    Filed: April 1, 2003
    Publication date: January 1, 2004
    Applicant: Cell Therapeutics, Inc.
    Inventors: J. Peter Klein, Anil M. Kumar, Marc J. McKennon
  • Method of screening compounds that inhibit lysophosphatidic acid acyltransferase
    Patent number: 6670143
    Abstract: Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: December 30, 2003
    Assignee: Cell Therapeutics, Inc.
    Inventors: David W. Leung, Daniel Adourel, David Hollenback
  • Manufacture of polyglutamate-therapeutic agent conjugates
    Publication number: 20030224971
    Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.
    Type: Application
    Filed: April 2, 2003
    Publication date: December 4, 2003
    Applicant: CELL THERAPEUTICS, INC.
    Inventors: Anil M. Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter
  • Polyglutamic acid-camptothecin conjugates and methods of preparation
    Publication number: 20030216289
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Application
    Filed: April 7, 2003
    Publication date: November 20, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Method for preventing tissue injury from hypoxia
    Publication number: 20030216414
    Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).
    Type: Application
    Filed: May 9, 2003
    Publication date: November 20, 2003
    Applicant: Cell Therapeutics,Inc.
    Inventors: Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
  • Polyglutamic acid-camptothecin conjugates and methods of preparation
    Publication number: 20030211973
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Application
    Filed: April 7, 2003
    Publication date: November 13, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Hydroxyl-containing compounds
    Publication number: 20030207901
    Abstract: Disclosed are therapeutic compounds having the formula:
    Type: Application
    Filed: May 14, 2003
    Publication date: November 6, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
  • Method for preventing tissue injury from hypoxia
    Patent number: 6638938
    Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: October 28, 2003
    Assignee: Cell Therapeutics, Inc.
    Inventors: Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
  • Aryl triazines as LPAAT-SS inhibitors and uses thereof
    Publication number: 20030153570
    Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor cells.
    Type: Application
    Filed: October 30, 2002
    Publication date: August 14, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A. Jenkins, J. Peter Klein, Anil M. Kumar, John Tulinsky
  • Tricyclic fused xanthine compounds and their uses
    Patent number: 6586429
    Abstract: Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling. The compounds have the following formulas where R1, R2 and R3 are defined in the written description of the invention.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: July 1, 2003
    Assignee: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, J. Peter Klein, Michael Coon
  • LPAAT-beta inhibitors and uses thereof
    Publication number: 20030100557
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.
    Type: Application
    Filed: September 6, 2002
    Publication date: May 29, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Robert Finney, David Leung, J. Peter Klein, David M. Hollenback, Lynn Bonham, Scott A. Shaffer, Norina M. Tang, Thayer H. White, John Tulinsky, Baoqing Gong
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Publication number: 20030099719
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Application
    Filed: September 30, 2002
    Publication date: May 29, 2003
    Applicant: Memorial Sloan-Kettering Cancer Center Cell Therapeutics, Inc.
    Inventors: Raymond P. Warrell, Pier P. Pandolfi, Janice L. Gabrilove, Ralph Ellison, Steven Soignet
  • Water soluble paclitaxel derivatives
    Publication number: 20030073615
    Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.
    Type: Application
    Filed: May 17, 2002
    Publication date: April 17, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Chun Li, Sidney Wallace, Dong-Fang Yu, David J. Yang
  • Manufacture of polyglutamate-therapeutic agent conjugates
    Publication number: 20030054977
    Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.
    Type: Application
    Filed: July 18, 2002
    Publication date: March 20, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Anil Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter
  • Effect of growth hormone and IGF-1 on neural stem cells
    Publication number: 20030054551
    Abstract: The present invention provides a method of increasing neural stem cell numbers by using growth hormone and/or IGF-1. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 20, 2003
    Applicant: Stem Cell Therapeutics Inc.
    Inventors: Tetsuro Shingo, Samuel Weiss
  • Prolactin induced increase in neural stem cell numbers
    Publication number: 20030054998
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 20, 2003
    Applicant: Stem Cell Therapeutics Inc.
    Inventors: Tetsuro Shingo, Samuel Weiss
  • Combined regulation of neural cell production
    Publication number: 20030049838
    Abstract: This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 13, 2003
    Applicant: Stem Cell Therapeutics Inc.
    Inventors: Bradley G. Thompson, Samuel Weiss, Tetsuro Shingo